Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Finke

Showing results (131-140 of 180) with videos related to

Pageof 18
Sort By:
American Journal of Hematology|September 9, 2014
Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a Mayo Clinic-French Consortium StudyEmnet A Wassie, Raphael Itzykson, Terra L Lasho, et al.
American Journal of Hematology|December 24, 2017
JAK2 exon 12 mutated polycythemia vera: Mayo-Careggi MPN Alliance study of 33 consecutive cases and comparison with JAK2V617F mutated diseaseAyalew Tefferi, Sravanthi Lavu, Mythri Mudireddy, et al.
Data in Brief|September 25, 2015
Biophysical characterization data on Aβ soluble oligomers produced through a method enabling prolonged oligomer stability and biological buffer conditionsAmanda C Crisostomo, Loan Dang, Jyothi L Digambaranath, et al.
Leukemia|April 4, 2014
ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patientsM M Patnaik, R Itzykson, T L Lasho, et al.
Analytical Biochemistry|April 30, 2015
Kinetic analysis of IgG antibodies to beta-amyloid oligomers with surface plasmon resonanceAmanda C Crisostomo, Loan Dang, Jyothi L Digambaranath, et al.
Leukemia Research|November 10, 2019
Functional evaluation of isocitrate dehydrogenase 1 and 2 variants of unclear significance in chronic myeloid neoplasmsAlexander Tischer, Guadalupe Antelo, Giacomo Coltro, et al.
Leukemia|October 23, 2009
JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survivalA Tefferi, T L Lasho, M M Patnaik, et al.
Leukemia|September 24, 2010
IDH mutations and trisomy 8 in myelodysplastic syndromes and acute myeloid leukemiaD Caramazza, T L Lasho, C M Finke, et al.
American Journal of Hematology|February 9, 2018
Mutations and prognosis in myelodysplastic syndromes: karyotype-adjusted analysis of targeted sequencing in 300 consecutive cases and development of a genetic risk modelNaseema Gangat, Mythri Mudireddy, Terra L Lasho, et al.
Blood Advances|February 23, 2018
Targeted next-generation sequencing in blast phase myeloproliferative neoplasmsTerra L Lasho, Mythri Mudireddy, Christy M Finke, et al.
Pageof 18

Showing results (131-140 of 180) with videos related to

Sort By:
Pageof 18
American Journal of Hematology|September 9, 2014
Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a Mayo Clinic-French Consortium StudyEmnet A Wassie, Raphael Itzykson, Terra L Lasho, et al.
American Journal of Hematology|December 24, 2017
JAK2 exon 12 mutated polycythemia vera: Mayo-Careggi MPN Alliance study of 33 consecutive cases and comparison with JAK2V617F mutated diseaseAyalew Tefferi, Sravanthi Lavu, Mythri Mudireddy, et al.
Data in Brief|September 25, 2015
Biophysical characterization data on Aβ soluble oligomers produced through a method enabling prolonged oligomer stability and biological buffer conditionsAmanda C Crisostomo, Loan Dang, Jyothi L Digambaranath, et al.
Leukemia|April 4, 2014
ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patientsM M Patnaik, R Itzykson, T L Lasho, et al.
Analytical Biochemistry|April 30, 2015
Kinetic analysis of IgG antibodies to beta-amyloid oligomers with surface plasmon resonanceAmanda C Crisostomo, Loan Dang, Jyothi L Digambaranath, et al.
Leukemia Research|November 10, 2019
Functional evaluation of isocitrate dehydrogenase 1 and 2 variants of unclear significance in chronic myeloid neoplasmsAlexander Tischer, Guadalupe Antelo, Giacomo Coltro, et al.
Leukemia|October 23, 2009
JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survivalA Tefferi, T L Lasho, M M Patnaik, et al.
Leukemia|September 24, 2010
IDH mutations and trisomy 8 in myelodysplastic syndromes and acute myeloid leukemiaD Caramazza, T L Lasho, C M Finke, et al.
American Journal of Hematology|February 9, 2018
Mutations and prognosis in myelodysplastic syndromes: karyotype-adjusted analysis of targeted sequencing in 300 consecutive cases and development of a genetic risk modelNaseema Gangat, Mythri Mudireddy, Terra L Lasho, et al.
Blood Advances|February 23, 2018
Targeted next-generation sequencing in blast phase myeloproliferative neoplasmsTerra L Lasho, Mythri Mudireddy, Christy M Finke, et al.
Pageof 18